[Lani]

.Ongoing randomized phase III trials in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer.

Clinical trial
NEFERTT
(N = 1200)
First-line metastatic
BO22589
(N = 1092)
First-line metastatic
EMILIA
(N = 580)
Locally advanced or metastatic
PHEREXA
(N = 450) Second-line after trastuzumab
BOLERO-1
(N = 717)
First-line metastatic
BOLERO-3 (N = 572) Resistant to trastuzumab
Study arms
Neratinib + Paclitaxel Trastuzumab + Paclitaxel
Herceptin + taxane T-DM1
T-DM1 + pertuzumab
T-DM1
Capecitabine + lapatinib
Docetaxel + trastuzumab + pertuzumab
Capecitabine + trastuzumab Capecitabine + trastuzumab +
Pertuzumab
Pertuzumab + trastuzumab Pertuzumab + trastuzumab + everolimus
Vinorelbine + trastuzumab Vinorelbine + trastuzumab +
everolimus

Trial endpoint/ WHEN Data expected:
PFS, OS 2012
PFS 2012
PFS, OS, ORR 2013
PFS, TTP, TTF, ORR, CBR 2015
PFS, OS, ORR, CBR, TTR 2012
PFS, OS, ORR, CBR 2012
CBR, clinical benefit rate; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTF, time to treatment failure; TTP, time to progression; TTR, time in treatment range.